日本Ⅲ期结直肠癌患者接受辅助氟尿嘧啶单药治疗时毒性与生存结局的性别差异:4项随机对照试验的汇总分析(JCOG2310A)
该汇总分析纳入4项随机对照试验中接受辅助氟尿嘧啶单药治疗的3170例日本Ⅲ期结直肠癌患者(女性1516例,男性1654例),比较两性不良事件发生率与生存结局。女性相对剂量强度≥90%的比例较低(59.1% vs 67.6%),需要减量的比例较高(28.8% vs 20.4%),完成辅助化疗的比例较低(77.0% vs 81.7%);女性3-4级不良事件发生率较高(OR 1.80,95%CI 1.51-2.14)。多因素分析显示女性是总生存(HR 0.80,95%CI 0.65-0.97)和无复发生存(HR 0.73,95%CI 0.63-0.85)的有利预后因素,女性5年复发时间事件发生率低于男性(17.7% vs 22.3%)。
要点
- 女性相对剂量强度≥90%的比例低于男性(59.1% vs 67.6%),需减量比例高于男性(28.8% vs 20.4%)。
- 女性3-4级不良事件发生率高于男性(OR 1.80,95%CI 1.51-2.14)。
- 女性总生存(HR 0.80,95%CI 0.65-0.97)和无复发生存(HR 0.73,95%CI 0.63-0.85)优于男性。
核心结论
- 性别与日本Ⅲ期结直肠癌患者接受辅助氟尿嘧啶单药治疗时不良事件的发生及生存结局相关。
研究设计与样本
- 汇总分析4项随机对照试验中接受辅助氟尿嘧啶单药治疗的Ⅲ期结直肠癌患者,共3170例(女性1516例,男性1654例),比较女性与男性的不良事件发生率和生存结局。
主要发现
- 女性相对剂量强度≥90%的比例为59.1%,男性为67.6%。
- 女性需要减量的比例为28.8%,男性为20.4%;女性完成辅助化疗的比例为77.0%,男性为81.7%。
- 多因素分析显示女性3-4级不良事件发生率高于男性(OR 1.80,95%CI 1.51-2.14)。
- 多因素分析显示女性总生存优于男性(HR 0.80,95%CI 0.65-0.97),无复发生存优于男性(HR 0.73,95%CI 0.63-0.85)。
- 女性5年复发时间事件发生率为17.7%,男性为22.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluoropyrimidine remains the key agent of adjuvant chemotherapy for stage III colorectal cancer (CRC). Western studies have shown that female sex is a favorable prognostic factor after surgery, but it is also a risk factor for adverse events (AEs) during adjuvant chemotherapy with fluoropyrimidine. However, little is known about whether sex differences in treatment outcomes exist in this setting in the Asian population. METHODS: Patients with stage III CRC who received adjuvant fluoropyrimidine monotherapy in 4 randomized controlled trials were analyzed. Incidences of AEs and survival outcomes were compared between female and male patients. RESULTS: A total of 3170 patients (female, 1516; male, 1654) were included in this analysis. Compared with males, females were less likely to have a relative dose intensity (≥90 %: female 59.1 % vs. male 67.6 %), with a higher proportion of requiring dose reduction (28.8 % vs. 20.4 %) and a lower proportion of completing adjuvant chemotherapy (77.0 % vs. 81.7 %). Multivariable analyses demonstrated that female sex was associated with a higher incidence of grade 3-4 AEs (odds ratio 1.80 [95 % CI 1.51-2.14]). Female sex was identified as a favorable prognostic factor for overall survival (hazard ratio [HR]: 0.80 [0.65-0.97]) and relapse-free survival (HR: 0.73 [0.63-0.85]) in multivariable analyses. Female patients had fewer time-to recurrence (TTR) events than male patients (5-year TTR: 17.7 % vs. 22.3 %). CONCLUSION: Sex had implications for the development of AEs and survival outcomes of Japanese patients with stage III CRC who received adjuvant fluoropyrimidine monotherapy.
引用
- Hirano H, Kataoka K, Yamaguchi T, et al. Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A). Eur J Cancer. 2024. PMID: 39579641. doi:10.1016/j.ejca.2024.115139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。